Unknown

Dataset Information

0

Celecoxib pharmacogenetics and pediatric adenotonsillectomy: a double-blinded randomized controlled study.


ABSTRACT: Pediatric adenotonsillectomy (A&T) is associated with prolonged pain and functional limitation. Celecoxib is an effective analgesic in adult surgery patients; however, its analgesic efficacy on pain and functional recovery in pediatric A&T patients is unknown.During 2009-2012, children (age 2-18 yr) scheduled for elective A&T were enrolled in a single-centre double-blind randomized controlled trial. Study participants received either oral placebo or celecoxib 6 mg·kg(-1) preoperatively, followed by 3 mg·kg(-1) twice daily for five doses. The primary outcome was the mean "worst 24-hr pain" scores during postoperative days (PODs) 0-2 on a 100-mm visual analogue scale (VAS). Secondary outcomes for PODs 0-7 included co-analgesic consumption, adverse events, and functional recovery. The impact of the CYP2C9*3 allele - associated with reduced celecoxib hepatic metabolism - on recovery was considered.Of the 282 children enrolled, 195 (celecoxib = 101, placebo = 94) were included in the primary outcome analysis. While on treatment, children receiving celecoxib experienced a modest reduction in the average pain experienced over PODs 0-2 (7 mm on a VAS; 95% confidence interval [CI]: 0.3 to 14; P = 0.04) and a "clinically significant" reduction (? 10 mm on a VAS; P ? 0.01) on PODs 0 and 1. During PODs 0-2, the mean acetaminophen consumption was lower in the celecoxib group vs the placebo group (78 mg·kg(-1); 95% CI: 68 to 89 vs 97 mg·kg(-1); 95% CI: 85 to 109, respectively; P = 0.03). No differences in adverse events, functional recovery, or satisfaction were observed by POD 7. The CYP2C9*3 allele was associated with less pain and improved functional recovery.A three-day course of oral celecoxib reduces early pain and co-analgesic consumption; however, an increase in dose, dose frequency, and duration of dose may be required for sustained pain relief in the pediatric setting. The CYP2C9*3 allele may influence recovery. This trial was registered at: ClinicalTrials.gov: NCT00849966.

SUBMITTER: Murto K 

PROVIDER: S-EPMC4457100 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Celecoxib pharmacogenetics and pediatric adenotonsillectomy: a double-blinded randomized controlled study.

Murto Kimmo K   Lamontagne Christine C   McFaul Colleen C   MacCormick Johnna J   Ramakko Kelly-Ann KA   Aglipay Mary M   Rosen David D   Vaillancourt Regis R  

Canadian journal of anaesthesia = Journal canadien d'anesthesie 20150407 7


<h4>Background</h4>Pediatric adenotonsillectomy (A&T) is associated with prolonged pain and functional limitation. Celecoxib is an effective analgesic in adult surgery patients; however, its analgesic efficacy on pain and functional recovery in pediatric A&T patients is unknown.<h4>Methods</h4>During 2009-2012, children (age 2-18 yr) scheduled for elective A&T were enrolled in a single-centre double-blind randomized controlled trial. Study participants received either oral placebo or celecoxib 6  ...[more]

Similar Datasets

| S-EPMC9608962 | biostudies-literature
| S-EPMC6267033 | biostudies-literature
| S-EPMC3718309 | biostudies-literature
| S-EPMC8783351 | biostudies-literature
| S-EPMC8519492 | biostudies-literature
| S-EPMC5640301 | biostudies-literature
| S-EPMC5482907 | biostudies-literature
2023-09-01 | GSE226353 | GEO
| S-EPMC5671810 | biostudies-other
| S-EPMC3200555 | biostudies-literature